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Abstract 
 
Purpose: Dementia is associated with various alterations of the eye and visual function. 
Over 60% of cases are attributable to Alzheimer’s disease (AD), a significant proportion 
of the remainder to vascular dementia (VD) or dementia with Lewy bodies (DLB), while 
frontotemporal dementia (FTD), and Parkinson’s disease dementia (PDD) are less 
common. This review describes the oculovisual problems of these five dementias and the 
pathological changes which may explain these symptoms. It further discusses clinical 
considerations to help the clinician care for older patients affected by dementia. 
Recent findings: Visual problems in dementia include loss of visual acuity (VA), defects 
in colour vision and visual masking tests, changes in pupillary response to mydriatics, 
defects in fixation and smooth and saccadic eye movements, changes in contrast 
sensitivity function (CSF) and visual evoked potentials (VEP), and disturbance of 
complex visual functions such as in reading ability, visuospatial function, and the naming 
and identification of objects. Pathological changes have also been reported affecting the 
crystalline lens, retina, optic nerve, and visual cortex. Clinically, issues such as cataract 
surgery, correcting the refractive error, quality of life, falls, visual impairment and eye 
care for dementia have been addressed. 
Summary: Many visual changes occur across dementias, are controversial, often based on 
limited patient numbers, and no single feature can be regarded as diagnostic of any 
specific dementia. Nevertheless, visual hallucinations may be more characteristic of DLB 
and PDD than AD or FTD. Differences in saccadic eye movement dysfunction may also 
help to distinguish AD from FTD and PDD from DLB. Eye care professionals need to 
keep informed of the growing literature in vision/dementia, be attentive to signs and 
symptoms suggestive of cognitive impairment, and be able to adapt their practice and 
clinical interventions to best serve patients with dementia.  
 
Key words: Dementia, Visual dysfunction, Alzheimer’s disease (AD), Vascular dementia 
(VD), Dementia with Lewy bodies (DLB)  
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Introduction 
A significant part of current optometric practice is concerned with examining older 
individuals1 and this trend is likely to continue given the predicted increase in the life-
span worldwide. A major disorder causing changes in the oculovisual system in the older 
population is dementia defined as ‘a major degenerative disorder with evidence of 
substantial cognitive decline from a previous level of performance in one or more 
domains such as short-term memory, abstract thinking, judgment, language, and 
personality changes sufficiently severe to interfere with independence.’2 The majority of 
cases of dementia are due to Alzheimer’s disease (AD)3, a significant proportion of the 
remainder to vascular dementia (VD)4, either alone or in combination with AD (mixed 
dementia), and to dementia with Lewy bodies (DLB)5, while other causes such as 
frontotemporal dementia (FTD)6, dementia associated with Parkinson’s disease (PDD)7,8, 
Creutzfeldt-Jakob disease (CJD)9, systemic disease, or to drug use are rare.10 FTD is a 
particularly complex disorder and is associated with a number of clinical conditions such 
as behavioural variant FTD (bvFTD), FTD with motor neuron disease (FTD-MND), 
progressive non-fluent aphasia (PNFA), semantic dementia (SD), and progressive apraxia 
(PAX).11 FTD is therefore a clinical diagnosis and its associated pathological variants are 
termed frontotemporal lobar degeneration (FTLD).12 
 
Dementia is associated with a characteristic brain pathology which can also affect the eye 
and visual pathway, resulting in visual dysfunction.13 This review describes the major 
alterations in visual function that may occur in dementia and the pathological changes 
which may explain them. Some aspects of visual dysfunction described cannot be 
measured easily in clinical practice and the study of dementia is frequently carried out by 
multidisciplinary teams involving the collaboration of many types of professional. In 
addition, the review concentrates on types of dementia more likely to be encountered in 
practice, e.g., AD, VD, and DLB, but also includes some less common disorders such as 
FTD and PDD.7 Particularly rare dementias such as CJD9, corticobasal degeneration 
(CBD)14, and progressive supranuclear palsy (PSP)15, however, have not been included.  
 
 
 4 
Prevalence of dementia  
It is estimated that 24.3 million individuals worldwide have dementia and that there are 
4.6 million new cases recorded each year.16-18 The overall prevalence of dementia 
calculated by the European dementia meta-analysis (EURDEM) of all European studies is 
1.6% and 1% for males and females respectively in the 65-69 age class, rising to 11% and 
12.6% for males and females in the 85-89 age class.17 Various estimates have also been 
made of the prevalence of dementia attributable specifically to AD.18-20 With advancing 
age, the prevalence of AD is estimated at 19% in individuals 75-84 yrs, and at 30-35% 
for those older than 85 yrs. Of the different types of dementia, approximately 62% of 
cases are due to AD and 17% to VD alone, 10% to a combination of VD and AD, while 
DLB accounts for 4%, FTD for 2%, PDD for 2%, and all other causes collectively for 3% 
of dementias.16-20 
 
Diagnosis of dementia 
There are many conditions which can result in dementia (Table 1) and clinical diagnosis 
of any specific disorder can be challenging. However, using rigorous criteria, the viability 
of current clinical diagnosis compared with the pathological standard can be 90% or 
higher in certain studies.21 Diagnosis of a dementia is frequently based on ‘consensus 
criteria’, i.e., on the opinions of leading experts in the field regarding the clinical and 
pathological features most important in diagnosis. For example, diagnostic criteria for 
AD were developed originally by the 'National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Association' (NINCDS-ADRDA) work group22 and subsequently modified by the 
National Institute on Aging (NIA) - Reagan Institute.23 In addition, criteria for DLB are 
based on those of the ‘Consortium on Dementia with Lewy bodies (CDLB)’.24 The 
definitive diagnosis of a dementia, however, usually requires neuropathological 
examination of brain tissue, either at biopsy or post-mortem, and the identification of a 
specific molecular pathology.25 Hence, the deposition of aggregated or misfolded proteins 
in the brain either as intracellular neuronal cytoplasmic ‘inclusions’ (NCI), e.g., 
neurofibrillary tangles (NFT) and Lewy bodies (LB), or extracellular protein deposits in 
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the form of ‘senile plaques’ (SP) is characteristic of many dementias and an important 
feature in the pathological diagnosis of individual disorders.24 
 
Many changes affect the brain in AD but few of them are specific, most appearing as 
exacerbations of normal aging. Hence, there is atrophy of the cerebral hemispheres with 
narrowed gyri and expanded sulci accompanying a widening of the subarachnoid space.26 
These gross changes mainly affect frontal, temporal, and parietal lobes but may spare the 
occipital cortex, at least until later in the disease. The meninges are thickened by fibrosis 
and the ventricles dilated.27 White matter undergoes discolouration and may become 
vacuolated (‘spongiosis’) and there is a proliferation of glial cells (‘gliosis’) affecting the 
gray matter.27 The formation of SP and NFT is regarded as the defining histological 
feature of AD and these lesions occur in various cerebral cortical regions, including the 
visual cortex, and in the hippocampus.23,28,29 The most important molecular constituents 
of the SP and NFT are the abnormally aggregated proteins -amyloid (A)30and the 
microtubule associated protein (MAP) tau, respectively.25 
 
Similar types of pathology can be observed in other dementias. Hence, A deposits are 
also found in VD4, PDD8, and DLB.31,32 In addition, both PDD and DLB possess LB, the 
major molecular constituent of which is -synuclein and these disorders are therefore 
termed ‘synucleinopathies’.33 In addition, abnormally aggregated tau and transactive 
response (TAR) DNA-binding protein of 43kDa (TDP-43) are important in various forms 
of FTD.12 Recent research suggests that many of these pathological proteins may 
propagate through the brain along anatomical pathways by direct cell to cell transfer.34-36 
Hence, visual dysfunction due to degenerative brain disease could be dictated by 
topography, i.e., which visual areas of brain become affected and at what stage of the 
disease, and ultimately be determined by the spread of these proteins.37 Nevertheless, 
some of these results are still controversial and not sufficiently documented to be certain 
of their validity. 
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Visual dysfunction in dementia 
Visual dysfunction in AD, VD, FTD, DLB, and PDD is summarized in Table 2. Aspects 
of visual function are divided into various categories based largely on those described in 
AD, the disorder with the most extensive literature. Several factors need to be taken into 
account in interpreting these findings. First, most studies rely on clinical diagnosis of a 
dementia and therefore, on the criteria used and should be viewed with caution if the 
most rigorous consensus criteria have not been applied. In addition, it can be difficult to 
separate AD from VD and PDD from DLB and there are ‘mixed’ cases exhibiting 
features of these disorders. Second, clinical testing frequently involves a small number of 
dementia participants not graded according to degree of cognitive impairment while other 
studies may classify participants into a small number of categories, e.g., early, middle, 
and late stage AD or into mild, moderate and severe cognitive impairment. Hence, studies 
on small numbers of ungraded individuals should be viewed with considerable caution. 
Third, visual testing may be carried out using a variety of different objective and 
subjective methods. Hence, the effectiveness of some of these methods in testing 
participants especially those with severe dementia should be taken into account. Fourth, 
participants may have been visually assessed without having had an eye examination, and 
thus, without knowing if the optimal refraction has been used or if an ocular pathology 
was present. Koch et al.38, for example, investigated the prevalence of uncorrected visual 
disorders in AD individuals residing in two nursing homes in the USA. In 85 residents 
with dementia, 80 needed spectacle correction for presbyopia, myopia, or both. Of these, 
25 had not been using their spectacles regularly, nine with severe cognitive impairment 
did not request them, eight had lost or damaged their glasses, and eight had inappropriate 
prescriptions for correcting their vision. Minor refractive blur may not affect performance 
on testing such as visual field, critical flicker fusion frequency (CFFF), low spatial 
frequency contrast sensitivity (CS), motion detection, and colour vision tasks but is likely 
to significantly affect visual acuity (VA), high spatial frequency CS, and stereoacuity. It 
should also be noted that many aspects of visual function can be affected by age-related 
conditions such as cataract, age-related macular degeneration, and glaucoma. 
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Visual acuity  
 
In one of the earliest studies of VA in dementia, Teller cards were used to measure VA 
binocularly in non communicative nursing home residents.39 The authors reported that 
VA can be measured in about 20-30 minutes and suggested that this technique should be 
used for those residents in whom conventional acuity measurements are not possible. 
Shortly after, the results from a study where VA was measured on equal groups (n= 87) 
of AD individuals with mild to moderate dementia and controls showed a higher 
prevalence of near- and far-vision impairment in AD.40 In addition, the authors reported 
that poor VA was significantly correlated with the severity of cognitive dysfunction.  A 
parallel study using a HOTV chart failed to demonstrate VA deficits in individuals with 
mild to severe AD,41 and a more recent investigation using Snellen type letters failed to 
find differences in near or far VA in community-dwelling individuals with mild 
dementia, both in comparison to control subjects.42 Later on, in a large scale research 
investigation, two types of VA charts (recognition vs grating acuity) were compared in 
nursing home residents.43 Of all participants (n= 656) studied, 86% responded to VA 
testing in at least one eye, 84% could be tested using Teller cards while 73% were 
testable using ETDRS letters or Lea symbols. Of the participants with a mini mental state 
examination (MMSE) score of less than 10, and thus having more severe dementia, 41% 
were testable by recognition acuity and 61% by grating acuity (Teller cards). It was 
concluded that Teller cards could be used to test vision in cognitively impaired 
individuals not testable by conventional means. Another study presented clinical data 
based on eye examinations provided to older individuals (65 to 104 yrs of age) residing in 
long-term care units.44 From the 105 residents referred for an optometric eye 
examination, 92 (87.6%) had dementia (MMSE between 0 to 23). It was possible to do an 
ocular refraction with VA measurement in 78 (84.8%) of these 92 residents. For those in 
whom VA could be improved, it increased on average from 6/27 (20/90) to 6/12 (20/40). 
This study clearly indicated that VA can be measured clinically in a large proportion of 
institutionalized older residents with mild to severe dementia,44 findings that parallel the 
research results presented by Friedman.43 More recently, Teller cards and Lea symbols 
were used to measure grating and recognition acuity respectively, in subjects with AD 
(n= 20) and age-matched controls (n= 24).45 The results indicated that VA measured with 
 8 
the 2 techniques were well correlated, in agreement with earlier data.43 Finally, VA has 
been compared using six validated acuity charts in older residents (n= 30) from long-term 
care units suffering from mild to severe dementia.46 The results showed that it was possible to 
measure VA in all, but one, subjects with severe dementia. The charts that provided the 
lowest level of VA were the Teller cards and the ETDRS Patty pics, regardless of the level of 
dementia. On the other hand, the charts that provided the highest level of VA as well as the 
fastest responses were those displaying letters (ETDRS or Snellen). The authors hypothesized 
that letters are usually learned very early in life and thus, may be more easily retrieved from 
long-term memory compared to the other optotypes, in older individuals with dementia. 
Therefore, the results from this study suggest that VA should be measured with the regular 
letter charts in individuals with dementia, but that other charts can be used for those not able 
to respond to letters. Overall, these studies indicate that even if it is more challenging and if it 
requires more time to measure VA in older individuals with dementia,46 this test can be 
performed in most of them. These studies further agree that alternative VA charts, such as the 
Teller cards, should be used for those not able to respond to standard letter acuity charts. 
Finally, studies comparing VA in individuals with vs without dementia present controversial 
data indicating either no decrease in VA, or alternatively, a decrease in VA that is more 
important with the severity of the disease. 
 
Colour vision 
 
Some early studies of dementia suggested defective colour vision may be present in 
approximately 50% of individuals with AD.47,48 Studies of colour vision, however, have 
frequently not taken into account the presence of cataract, intraocular lenses and aphakia, 
or have not been using appropriate controls. Colour perception was compared in 
cognitively intact 80 and 95 yr old individuals and in participants with AD.49 Performance 
of the 95 yr olds was poorer than the 80 yr olds but similar to the AD participants, overall 
lower colour perception ability in the 95 yr olds being attributable to age rather than any 
additional factor. In a further study, although the number of participants was small (n= 
10), colour deficits identified in AD by L’Anthony D-15 desaturated colour test could be 
accounted for by age-related changes.50 Another study has also suggested that colour 
vision is normal in mild to moderate AD51, however, the authors acknowledged that their 
sample size was very limited (n= 12) and that the Ishihara and Ishikawa plates used 
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provide only a rudimentory measure of colour vision. In a study by Pache et al.52, both 
Ishihara plates and the saturated PV-16 choice test were used, the latter originally 
designed for children. Hence, there were significantly more unspecific errors made by 
individuals with mild to moderate AD (n= 26) compared to age-matched controls (n= 25), 
using both tests, but no relationship was detected between test performance and severity 
of AD. As the authors acknowledged, however, their VA scores were quite different after 
having balanced the groups for the presence of cataract. The authors suggest that this may 
be due to poor collaboration on the VA test, although only one subject had severe 
dementia. Other studies also identified colour vision deficiencies in mild dementia using 
the SPP2 plates42 and in mild to severe dementia using the City University test plates41. 
Unfortunately, the results of the various studies remain controversial and the strength of 
the evidence does not permit any real conclusion on the potential effect of AD on colour 
vision. Colour vision deficits may also occur in DLB53 but this disorder has been much 
less studied than AD. 
 
 
Stereoacuity 
 
In AD individuals, defects in binocular depth perception (‘stereoacuity’) have been found 
using the Randot dot stereograms,41,54 but another study using the Titmus test did not find 
differences.42 In a further study, functional magnetic resonance imaging (fMRI) was carried 
out on newly diagnosed (mild) AD individuals (n= 12) not taking anti-cholinesterase 
medication while they viewed various types of stimuli including stereomotion.55 AD 
individuals exhibited hypoactivation in area V5, and in the superior parietal lobule, parietal 
occipital areas, and premotor cortex compared with controls but with greater activity in the 
inferior parietal lobule, while viewing visuospatial stimuli. The authors conclude that these 
results are evidence for a pathophysiological basis for the visuospatial disorientation 
experienced by individuals with AD. Stereoacuity may be impaired more significantly in VD 
than in AD, pathology in the right hemisphere of the brain having a greater effect than in the 
left and by cortical rather than subcortical vascular pathology.56 Impairment in stereoacuity 
was related to the severity of dementia. Stereoacuity is mediated by various neural pathways 
involving the thalamus and posterior parietal lobe, areas likely to be affected in both AD and 
VD. Overall, these studies present some functional and pathophysiological evidence for a 
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deficit in stereoacuity in AD and VD. 
 
Contrast sensitivity function 
Contrast sensitivity (CS) provides a measure of visual performance for various spatial 
frequencies and contrasts. The CS performance of individuals with AD is controversial, 
some studies not reporting changes in the CS function (CSF)57,58 while others found 
reduced CS over all spatial frequencies59,60 and particularly at lower spatial frequencies.41 
Such differences have been attributed to variations in the population under study, the 
method used to measure CS, or the failure to account for VA differences.61 Additionally, 
not all studies checked for adequate ocular refraction, test distance or ocular health of 
participants. Spatial CS performance across a range of frequencies has been shown to be 
similar in AD, VD and mixed AD/VD cases.62 A study of spatial CS at frequencies 1, 5, 
and 8 cycles deg-1 using the sweep visual evoked potential (VEP),60 an objective method 
that minimizes the subjects' collaboration, showed a deficit in CS in mild to moderate AD 
(n= 16) vs control (n= 9) subjects. The authors concluded that defects in spatial CSF were 
likely attributable to dysfunction of the primary afferent visual pathway since they were 
not related to the severity of the disease. A more recent study used frequency doubling 
technology (FDT) to measure temporal CS in AD, amnestic mild cognitive impairment 
(MCI), older adults with cognitive complaints (CC) but without MCI, and healthy 
controls.63 CS deficits were found in all quadrants for AD, MCI and CC subjects, but the 
largest differences between AD and MCI compared to controls were found in the upper 
right visual field in both eyes. From these results, it was concluded that FDT based 
measures of temporal CS are sensitive to early AD changes and it was suggested that this 
type of testing may have promise as a biomarker for AD.63 The authors, however, were 
very careful in acknowledging the limitations of their results and the need for additional 
studies before this type of CS measurement can effectively be used as a biomarker of the 
disease. Although not universal, deficits have been reported in the vast majority of studies 
having investigated CS in AD. Deficits in CS were even hypothesized as leading to 
impaired cognitive performance in AD. This was demonstrated using a test of temporal 
CS at high frequency when enhancing the signal strength through an increase in stimulus 
contrast was shown to improve performance on a letter recognition task in subjects with 
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probable AD.64 An earlier study also demonstrated that increasing contrast improved the 
speed of letter identification while reading in AD.65 
 
Motion perception 
There are many aspects to motion perception such as detection, direction discrimination, 
perception of structure from motion. Earlier studies indicated that motion direction 
discrimination66,67 and perception of structure from motion42,57 are impaired in AD. It has 
been suggested that defective motion processing in AD individuals may have retinal, 
cortical and subcortical neuronal origin.57 Such anomalies in motion processing may 
explain visuospatial disorientation in AD68 and it has been suggested that it can also lead 
to unsafe driving behavior.69,70  
 
 
Critical flicker fusion frequency  
The CFFF threshold represents the lowest frequency at which a person can no longer 
perceive a flickering light as a steady light.71 The CFFF is a well-established research tool 
in psychopharmacology, with possible application in detecting early AD.71,72 Neurons 
from the retina and various cortical areas contribute to the CFFF.41,72 In a study of mild to 
moderate AD participants (n= 26), CFFF was highly correlated with standard clinical 
assessment, cognitive function, and psychomotor performance.73 However, CFFF has 
also been reported to be normal in AD.41 By contrast, Mentis et al.74 obtained positron 
emission tomography (PET) scans in mild to severe AD individuals (n= 21) while 
wearing goggles containing grids of red lights. In AD, there were significantly smaller 
cerebral blood flow responses at the frequency producing the largest responses in control 
subjects, which may indicate a deficit in CFFF. In one study, CFFF was able to 
differentiate between AD (n= 30) and VaD (n= 16), but these results need to be 
replicated.75 
 
 
Visual masking 
Psychophysical thresholds are regarded as more reliable than psychometric tests in 
assessing cognitive dysfunction in the elderly, and visual masking has been a particularly 
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useful test.76 Visual masking involves the presentation of a second stimulus, such as 
illumination or a checkerboard, immediately before (‘forward masking’) or after 
(‘backward masking’) a test stimulus. This type of testing helps probing spatial and 
temporal aspects of the visual-cognitive system at various levels of processing.77 It has 
been shown that the performance of AD individuals on a backward patterned mask 
stimulus is impaired compared with controls.58,78 This result suggests that the speed of 
central visual processing is further reduced in AD subjects compared to age-matched 
controls. In addition, it was shown that adaptation to the backward masking task may 
occur at different speeds in individuals with AD (n= 21) and VD (n= 16).79 Furthermore, 
in AD individuals (n= 38) with deficits on a backward masking task, 13 were tested 
electrophysiologically, the flash electroretinogram (fERG) and pattern VEP being 
normal, suggesting the involvement of visual association areas rather than precortical 
visual pathway.80 ‘Visual crowding’ is a specific form of masking in which the 
identification of a given letter is compromised by the presence of other letters in close 
proximity to the target.81 In one individual with a posterior form of AD (posterior cortical 
atrophy-PCA), recognition accuracy decreased significantly in the presence of flanking 
letters and hence, ‘crowding’ could constitute a specific form of early-visual processing 
deficit impairing reading. Overall, these results have shown that visual masking can 
reveal cortical as well as precortical visual deficits. 
 
 
Visual fields 
One earlier study reported an overall reduction in sensitivity in the visual field of AD 
individuals, with greater deficits inferiorly.82 Follow up studies demonstrated a 
progression of visual field loss over time.82 This result is in contrast to those in a more 
recent study63 where deficits in older individuals with AD (n= 10) and MCI (n= 28), were 
found especially in the upper right visual field, using frequency doubling technology 
(FDT). Although additional studies are essential to reconcile these results, such visual 
field deficits could reflect differential thinning of the retina in AD or differences in 
pathology affecting primary visual cortex (VI).83 The feasibility of using FDT to screen 
for AD biomarkers was discussed in a recent paper.84 Although it was demonstrated that 
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AD individuals can respond well to the test, further larger-scale studies are required to 
confirm these results in individuals with AD and MCI. 
 
In addition, a number of imaging studies have been carried out on individuals with 
clinically diagnosed DLB and the results compared with AD. For example, regional 
cerebral blood flow (rCBF) is usually lower in occipital cortex85,86 and higher in the 
medial temporal lobe86 in DLB than in AD. In both DLB and AD, there are significant 
reductions in metabolism in parietal and temporal cortex, the posterior cingulate gyrus, 
and frontal association areas.87 However, a significant reduction in occipital cortex and 
especially in area V1 occurred only in DLB, and therefore, there is considerable potential 
for visual field deficits in this disorder. Consistent with this suggestion, a study of a 
single 66 yr old person diagnosed with DLB, revealed a left homonymous hemianopia 
early in the disease.88 Although neuropathologic findings met the criteria for DLB, large 
numbers of NFT were also found in the right striate, peristriate, and inferior temporal 
cortex of this person, possibly explaining the visual field deficits. In addition, occipital 
hypometabolism may be a useful potential method of distinguishing DLB from AD.85-87 
 
Pupillary function 
Earlier reports suggested that individuals with AD displayed a specific response to low 
doses (typically 0.01%) of the muscarinic receptor antagonist tropicamide, with pupils 
dilating on average by 23.4% compared to 5% for controls.89 Although these findings 
could be replicated in some studies90,91, others did not find similar results.92,93 Increased 
pupillary sensitivity to tropicamide could be due to loss of noradrenergic neurons in the 
locus caeruleus observed in AD and a number of dementias.94 
 
Hypersensitivity pupillary responses have also been reported using dilute solutions of the 
sympathetic agonist phenylephrine and the cholinergic agonist pilocarpine.95 
Phenylephrine 0.5% induced a larger mydriasis in LBD subjects compared to AD and 
control participants, a result attributed to the dysfunction in sympathetic innervation to 
the iris. Pilocarpine 0.0625% induced more miosis in DLB and AD subjects compared to 
controls, a result attributed to the dysfunction of the cholinergic system in both diseases. 
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Hence, it was concluded that a combination of the pilocarpine and phenylephrine pupil 
tests may help detect the two disorders as well as distinguish between them. Reduction in 
the pupillary constriction to bright light has also been reported in AD individuals but the 
responses were highly variable between subjects.96 
 
Up to now, the results of these studies have not been sufficiently convincing to find their 
way within the clinical setting. 
 
Eye movements 
Eye movement problems are particularly characteristic of dementia especially in the 
parkinsonian syndromes DLB and PDD.5,7 Assessment of oculomotor function has 
usually been carried out using equipment able to measure precisely spatial and temporal 
eye movement events, and employing electro-oculography (EOG) on individuals in 
whom cognitive impairment was not serious enough to compromise the tests. 
 
The ability of some individuals to fixate a target is affected in AD97,98, defects of fixation 
control being associated with parietal lobe degeneration, a region involved in maintaining 
fixation stability. Several changes in saccadic eye movements have also been reported in 
AD. Saccadic latency is prolonged in AD97-102 and it was even found that longer latencies 
correlated with lower MMSE scores.102 The velocity of saccades is reduced and the 
degree of reduction correlates with the severity of dementia.97 Individuals with AD make 
hypometric saccades97 and many have difficulty initiating or maintaining saccadic eye 
movements.103 In AD individuals, the duration of fixation during visual saccades 
increased in the early stages of the disease.104 By contrast, some VD individuals were 
slower to adapt to this task and required longer center to target distances, believed to be 
attributable to a general slowing of cognitive processes in VD.104 
 
Smooth pursuits, a sensitive indicator of brain function, may also be affected in AD.105 
Hence, a gradual deterioration of these movements has been reported necessitating 
‘catch-up saccades’ to maintain fixation.100,106  Degeneration and atrophy of frontal and 
parietal lobes have been implicated in these changes.3 In particular, dorsal frontal lobe 
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damage impairs smooth pursuits and the ability to suppress visually guided saccades on 
the antisaccade task.107 
 
Abnormalities of saccadic eye movements are also characteristic of various forms of 
FTD. Hence, in a study comparing FTD (n= 22) and control (n= 23) subjects, saccadic 
latency was prolonged and early saccades were increased, reflecting increased atrophy of 
the left frontal eye field and reduced speed of decision making processes.108 In addition, a 
study demonstrated that FTD (n= 28) subjects presented abnormalities in reflexive 
visually guided saccades, as did AD (n= 10) participants.109 In a smaller size study of 
FTD associated with motor neuron disease (MND), and in whom gross ocular 
abnormalities were present, slowing of both vertical and horizontal saccades was 
observed.110 In a much larger study (n> 100) comparing various forms of FTD and other 
related disorders, an overlap was observed between most groups, but only in FTD were 
there spontaneous selfcorrecting anti-saccade errors.111 In addition, mutual gaze (‘eye 
contact’), which is important in social interactions, is impaired in a number of dementias 
including FTD, but was preserved in AD subjects.112 There is also a significant difference 
in the ability of control and AD subjects to reaccelerate their eyes in a predictive fashion 
before the predicted time of target reappearance, FTD being unable to carry out this task. 
Moreover, in FTD, anticipatory eye movements are triggered by the disappearance of the 
fixation point before the onset of target motion.113 
 
In a study comparing DLB (n= 20), PDD (n= 20) and AD (n= 22) subjects, DLB and 
PDD participants showed impairment in reflexive and saccadic execution as well as in the 
performance of more complex saccadic eye movements, differentiating them from those 
with AD.114 In addition, albeit in a single case with DLB, problems in convergence were 
followed by bradykinesia and rigidity.115 There have also been cases of DLB presenting 
with vertical and horizontal gaze palsy, a sign frequently associated with PSP, thus 
potentially confusing the two disorders.116 Caution is therefore required in the 
interpretation of vertical gaze palsy when distinguishing parkinsonian syndromes.117 
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Electroencephalogram 
Studies of six electroencephalogram (EEG) frequency bands in FTD (n= 19) and AD (n= 
16) subjects indicate that there was no increase in slow activity and a larger decrease in 
fast activity in FTD, while there was an increase in slow activity and a smaller decrease 
in fast activity in AD, in comparison to age-matched controls.118 Quantitative EEG alone, 
however, could not differentiate well FTD and AD. In a study of VD (n= 12), there was a 
reduction in synchrony of the slow frequency bands during a target detection task, more 
neurons presumably having to be activated.119 It was concluded that this type of EEG 
recording can be useful to evaluate cognitive dysfunction in individuals with VD. EEG in 
response to eye opening and to 12 Hz photic stimulation was also studied in a relatively 
small number of DLB (n= 10) and PDD (n= 7) subjects using global field 
synchronization (GFS).120 When eyes were closed, theta-GFS increased in PDD and 
alpha-1 GFS was decreased in DLB. In addition, using 12 Hz intermittent photic 
stimulation, reactivity of posterior electrodes was decreased in DLB, suggesting 
disruption of posterior anatomical pathways.120 Further studies are required, however, to 
evaluate if EEG can distinguish LBD from PDD.    
 
Electroretinogram  
Changes in the electroretinogram (ERG) have been reported in various dementias. The 
pattern ERG (PERG) reflects the activity of the retinal and pre-retinal ganglion cells.121 It 
has been reported that the amplitude and latency of the PERG response are reduced in 
AD,122-125 although these results are not universal.126,127 The flash ERG (fERG) measures 
the activity of the photoreceptors, bipolar, Mueller and amacrine cells. Studies have 
indicated that the scotopic and photopic fERG are largely unaffected in AD.80,127,128 It has 
further been shown that the scotopic and photopic oscillatory potentials are also 
preserved in AD.128 
 
The fERG has also been used to demonstrate dysfunction of the scotopic and photopic 
systems of the retina in DLB subjects.129 The deficits were attributed to pathological 
alterations in the photoreceptors which were accompanied by ‘pale inclusions’ in the 
outer plexiform layer, particularly in the peripheral retina. Immunohistochemistry and 
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structural analyses indicated that these inclusions differed from LB.130 
 
Visual evoked potentials 
The visual evoked potentials (VEP) provide an objective measure of the functionality of 
the maculo-cortical pathways. In AD, a number of studies suggest that the latency of the 
P2 component of the cortical flash VEP is delayed, while the P100 component to a 
reversing checkerboard stimulus is unaffected.131-134 This combination of abnormalities, 
however, is controversial and has not been confirmed by all studies.135 Others have found 
that the P100 is delayed and that the retinocortical time is prolonged in AD.125,136 
 
Visual event-related potentials 
A number of studies of event-related potentials which elicit the ‘P3’ (P300) response 
believed to reflect orientation, attention, stimulus evaluation, and memory have been 
carried out in dementia. It is also believed that P300 is an indication of the level of 
cognitive resources used for processing a stimulus.137 Using a facial discrimination 
task138, mean latency of the visual P3 response was greater in PDD with visual 
hallucinations (n= 11) and DLB (n= 24) compared to AD (n= 21) subjects.  Furthermore, 
mean latency of the P2 response was greater in PDD with and without VH and in DLB 
subjects, but not in AD, compared with controls. The results suggest that visual cognitive 
function is selectively impaired in PDD and DLB, and this, at an early stage of visual 
processing. In VD, the latency of P3 is delayed and its amplitude decreased, suggesting 
that these individuals may have fewer attention resources to devote to processing 
stimuli.139  
 
Complex visual functions 
Individuals with dementia exhibit a variety of more complex visual problems. This is the 
case for example with reading103,140 or visuospatial function.48,141,142 Three types of 
reading problem are common in AD: 1. ‘semantic alexia’, caused by a failure to 
understand words, primary vision being unimpaired, 2. ‘surface alexia’, caused by 
difficulties in pronouncing words, and 3. ‘letter by letter reading’, a difficulty in decoding 
words that are presented visually, not reading complete words but their constituent letters 
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in sequence.143 Individuals with AD also show deficits in eye-head coordination144, 
difficulties with finding objects that are surrounded by other items145, and in finding 
known objects in an unknown location.146 AD and VD individuals often exhibit very 
similar deficits on more complex visual tasks, with the possible exception of word recall, 
which is frequently better in VD.147 
 
In some cases of FTD, difficulties in recognizing faces from photographs, including those 
of well-known personalities and family members, have been observed.148,149 Facial 
recognition problems may by characteristic of FTD and therefore, a useful potential 
diagnostic indicator. In addition, the drawing performance of four artists with FTD was 
investigated, none with facial recognition problems, and in three out of four, drawings of 
faces were ‘distorted’ or ‘menacing’.150 These individuals exhibit cortical degeneration 
specifically affecting frontal and temporal regions and which could affect those areas 
involved in processing facial data. Hence, in SD, pathology in the anterior and inferior 
lateral right temporal lobe may be responsible.151 
 
Individuals with DLB (n= 24) had a poorer performance than those with AD (n= 48) on 
object size discrimination, form discrimination, overlapping figure identification, and on 
visual counting tasks.152 This was concluded to play a role in the perceptual deficits 
observed in DLB, such as visual hallucinations. Other complex visual tasks such as 
colour integration and rotated object comparison are also impaired in DLB, which 
corresponds with the cortical areas affected by the disease.153 Significant defects in the 
‘trail-making task’, a test of visual attention in which the subject is asked to ‘connect the 
dots’ and on the DMS-48, a test of visual object recognition memory, were observed in 
DLB (n= 10) compared to PDD (n= 12) individuals.154 Although further studies are 
required, the authors concluded that such tests can be useful for characterizing the two 
diseases. 
 
Individuals with DLB may exhibit a variety of deficits in visuospatial function including 
difficulty in judging verticals and the position of body parts, and in carrying out a route-
walking task.5 Hence, inability to copy the shape of a pentagon was often worse in DLB 
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(n= 17) than AD (n= 27) individuals suggesting greater visuospatial deficits.155 By 
contrast, in a large study of FTD participants (n= 44), seven of whom were pathologically 
confirmed, there was relative preservation of visuospatial function156, although such 
deficits have been reported in late-onset cases.157 Individuals with AD, although rarely, 
may develop a complex combination of visual symptoms called 'Balint's syndrome', 
usually before any signs of overt dementia are apparent.158  These include ocular apraxia, 
a psychic paralysis of gaze, optic ataxia, a defective visually controlled hand movement, 
and simultanagnosia, a visuospatial disorder of attention.158 Simultanagnosia can be 
accompanied by visual field constriction, the fading of centrally fixated objects, and 
impaired reading ability, despite normal VA. 
 
 
Visual hallucinations 
 
Visual hallucinations (VH) have been reported in several types of dementias, especially 
in individuals with decreased VA or those with advanced cognitive impairment.159 Hence, 
in a study of PDD (n= 26), hallucinations were very common.160 Hallucinations are also 
common in DLB161 but are less frequent in AD.162-165 VH have also been reported in 
some genetic subtypes of FTD, especially those caused by chromosome 9 open reading 
frame 72 (C9ORF72) gene mutations.166  In a small study of DLB individuals (n= 9), six 
developed VH and it was the presenting sign in one case.161 VH in DLB are recurrent, 
well formed and detailed167 and may be the only psychotic symptom which can reliably 
differentiate DLB and AD.5 Hallucinations in DLB are usually colourful and complex,168 
and involve people or animals invading the person's home.161 The hallucinations are often 
seen in great detail and although they do not often trouble the person, they can evoke 
considerable fear in some.161,169  
 
Various factors may be involved in VH in DLB (Fig 1). Although pathology affecting the 
thalamus may be a contributory factor170, changes in cerebral cortex are more likely to be 
the cause. Hence, hallucinations are abolished by eye closure indicating a primary 
cortical pathology.171 Hypometabolism in area V1 of the visual cortex and relatively 
preserved metabolism in the temporal and parietal lobes may be associated with these 
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symptoms. Well formed VH are also evident in a pathological study of subjects (n= 63) 
with extensive development of LB in the temporal lobe172 and are rarely reported in 
parkinsonian syndromes without LB, such as PSP.173 Furthermore, cholinergic activity, 
especially the enzyme choline acetyltransferase (CAT) is reduced in the cerebral cortex 
of individuals with DLB.174 More extensive cholinergic abnormalities are associated with 
an increased risk of VH. Hence, hallucinations in DLB could result from a change in the 
balance of neurotransmitter activity between the cholinergic and monoaminergic systems 
as a consequence of LB pathology in brain stem nuclei.165 Nevertheless, ocular and 
retinal pathology could also contribute to hallucinations by reducing occipital 
stimulation.130,175,176 Hence, the ‘pale inclusions’ which have been observed in the outer 
plexiform layer of the retina in DLB may suggest disruption of the cytoskeleton of cone 
cells.129 As a consequence, ventral association areas may increase their activity as a result 
of cortical disinhibition resulting in hallucination. 
 
Visual hallucinations have been linked with decreased visual acuity in AD177-179, and 
observational data indicate that adjusting the ophthalmic correction can reduce VH.179 A 
case reports study showed that providing optical aids decreased VH in three older 
individuals affected by VD and mild dementia.180 Another case report presented an older 
patient incorrectly assumed to have a form of senile psychosis, in whom VH ceased 
completely after having had cataract surgery.181 Further studies are required, however, 
before solid conclusions can be drawn regarding the effectiveness improving vision has 
on reducing VH in the various forms of dementia. 
 
Pathological changes in the eye and visual system 
 
Anterior segment of the eye 
Some studies have reported Aβ deposits, which are widespread in AD brain in the form 
of SP, in the crystalline lens of the eye. Hence, Aβ deposits were observed in the 
equatorial supranuclear region of the lens, a mitotically active region not usually affected 
by cataract, in postmortem eyes of all AD subjects (n= 9) and in none of the controls.182 
Hence, a fluorescent compound which binds to Aβ deposits could be used in vivo as a 
potential early test for AD183, the fluorescent material being applied as an eye ointment 
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and a laser scanning device used to measure the amount of fluorescence. However, 
Michael et al.184 studied the presence of Aβ in postmortem eyes of AD individuals using 
confocal Raman microspectroscopy and observed that cortical lens opacities were not 
typical of AD and not characterized by the accumulation of Aβ and hence, the occurrence 
of Aβ in the lens in AD remains controversial. 
 
Posterior segment of the eye 
Whether or not pathological changes occur within the posterior segment of the eye in 
dementia is also controversial. In an earlier study, the authors did not detect fundus 
abnormalities linked with AD.54 Nevertheless, others have reported abnormalities in some 
individuals with AD, including disc pallor, optic atrophy, and disc cupping.103 
 
In various dementias, transynaptic degeneration involving the posterior visual pathway 
may cause pathological changes in the eye and retina.185 Hence, the retina could provide 
an easily accessible site for non-invasive examination of brain pathology.186 Retinal nerve 
fibre layer (RNFL) abnormalities in AD and controls have been studied using optical 
coherence tomography (OCT), a simple, high resolution method of quantifying the 
thickness of the RNFL.187 This technique was originally used to study glaucoma and non-
glaucomatous neuropathies.188 A number of studies of RNFL using OCT have been 
carried out in AD. Hence, a study of AD (n= 21) and control (n= 21) subjects revealed 
thinning of RNFL and RNFL plus ganglion cell layer189, while thinning of RNFL in all 
retinal quadrants was apparent in a meta-analysis of seven studies involving 324 eyes190, 
and in other studies thinning most significantly affected the superior and/or inferior 
quadrants of the retina.191,192 RNFL thinning has also been observed at the macula in a 
study of 28 eyes from AD individuals (n= 14).193 RNFL thinning at the macula may also 
be accompanied by decreased electrical activity of the macula.194 In addition, retinal 
thinning has been recorded in MCI, a condition which may precede AD, suggesting that 
the retina may be affected early in the disease.195,196 Thinning of RNFL has also been 
recorded in 10 cases each of PDD and DLB.187 
 
Post-mortem studies of the retina in AD also suggest a decreased number of ganglion 
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cells and a thinning of the RNFL.197 There is a swelling and shrinking of ganglion cells 
with some containing vacuoles. A decline in the number of retinal ganglion cells could 
explain the disc abnormalities observed in a study of individuals with AD (n= 26).198 It 
was unlikely that primary open-angle glaucoma (POAG) explained these changes as the 
intraocular pressures were in the normal range, and there was no family history of 
glaucoma198, but low tension glaucoma could not be ruled out. SP-like structures have 
also been recorded in the human retina and in transgenic rodent models of AD199 
suggesting that retinal imaging techniques could eventually be applied to monitor retinal 
SP.200 AD-related pathological changes have also been observed in normal-pressure 
hydrocephalus, traumatic brain injury, and glaucoma; all of which may be associated with 
elevated intracranial or intraocular pressure.201 These results suggest that AD-type 
changes could result in part from exposure of the central nervous system to elevated 
mechanical stress202 and that such progressive changes in pressure gradients affecting the 
intracranial optic nerve might be a further cause of visual field changes in AD. 
 
Optic nerve 
POAG may be present in approximately a quarter of individuals with AD compared with 
5-10% of controls,203,204 the authors suggesting that similar pathological processes could 
occur in the two diseases. By contrast, in a large Danish study, no association was found 
between POAG and AD.205 Abnormal tau proteins have also been observed in the retina 
and optic nerve in AD, FTD, and in glaucoma.206 
 
There is a decline in the density of optic nerve axons in AD. Studies have reported either 
a preferential reduction in large-diameter axons197,207 or a decline in small-diameter axons 
in individuals with AD (n= 12).208 Whether this degeneration is caused by a loss of retinal 
ganglion cells, retrograde degeneration affecting the retina, or both of these processes is 
yet to be established. 
 
A reduction in large-diameter axons in the optic nerve suggests that the magnocellular 
(M) pathway is impaired in AD. The M-pathway, stimulated using high temporal - low 
spatial frequency, low contrast and luminance stimuli, is essentially a ‘luminance’ 
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channel involved in motion detection.209 Its preferential degeneration could explain 
reported anomalies in the cortical flash VEP210,211 and loss of motion perception observed 
in AD. If small-diameter axons in the optic nerve are affected, then it suggests that the 
parvocellular (P) pathway is impaired in AD. This would likely impair the detection of 
fine details or colour.209 Consistent with this, impairment of colour vision has been 
reported in AD.48 
 
Lateral geniculate nucleus 
Neurons in the lateral geniculate nucleus rarely develop NFT, although cells in this area 
accumulate lipofuscin, a pigment found in increasing amounts in nerve cells with age.212 
In an earlier study, however, SP were observed in all AD individuals (n= 12) 
evaluated.213 
 
Visual cortex 
Functional magnetic resonance imaging (fMRI) studies of young and healthy older adults 
suggest no major changes in visual cortex due to aging, but changes have been reported 
in some AD cases.214 The transition between normal aging, MCI, and AD is often 
indistinct but pathological changes suggest early changes in medial temporal lobe 
spreading to affect neocortical regions215 while brain imaging studies often suggest early 
changes in the posterior/temporal parietal region and in occipital cortex with NFT 
affecting B19 (V3).216 These observations support the hypothesis that retinal pathology in 
AD may result from retrograde degeneration from association areas reducing axonal input 
to the eye. Pathological changes when they affect the visual cortex usually involve visual 
association areas (V2, V3 etc.) more significantly than area V1. Hence, SP and NFT were 
found in the visual cortex in 72% and 27% of AD individuals (n= 106), respectively.217 
The density of SP and especially NFT was more important in area V2 than in V1, 
particularly in early-onset cases. In V1, SP with distinct amyloid cores accompanied by 
small numbers of NFT can be seen, whereas in V2, numerous NFT and uncored 'neuritic-
type' SP are usually found.218 Additional studies are required to evaluate whether or not 
the differences in cortical pathology in V1 and V2 can explain the cortical VEP responses 
reported in AD.219 In addition, in many cases of AD, the density of SP and/or NFT in V1 
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is significantly greater in the cuneal vs the lingual gyrus.83 These findings could help 
explain the predominantly inferior visual field deficits that have been reported in some 
cases of AD.82 Furthermore, a reduction in myelin as well as a loss of neurons and 
neurotransmitters have also been reported in the outer laminae of the visual cortex.218 
 
 
Clinical considerations 
 
Cataract surgery  
 
Studies indicate that much of the vision loss in individuals residing in nursing homes may 
be correctable, due to causes such as inappropriately corrected refractive error or 
unoperated cataract. Cataracts are highly prevalent with advancing age220 and the 
incidence of cataract surgery is increasing in many developed countries.221 The benefits 
cataract surgery has on functional vision and quality of life have been well documented 
for community-dwelling aging individuals,222,223 including the oldest-old.224 This latter 
study showed that those 90 yrs of age or older were the most unsatisfied with their vision 
prior to surgery and that 79% fared better in their activities of daily living after the 
surgery. Additionally, the surgery improved VA in more than 90%, and further showed 
that 43% and 62% of those 90 yrs of age or older and 85-89 yrs of age respectively, were 
still alive 4 years after surgery. The authors concluded that not only was surgery 
beneficial for improving vision, but it was also beneficial when you take life expectancy 
into account. Other studies also demonstrated the benefits of cataract surgery,225 as well 
as its safety221 for the very elderly. These studies, however, did not address such 
outcomes in older individuals with cognitive deficits, an issue of particular importance, as 
the prevalence of cognitive deficits and dementia increases with advancing age. It is 
likely that many of the older individuals seen by ophthalmologists for cataract surgery are 
affected by undetected cognitive decline, MCI or even dementia. Recently, Jefferis227 
presented data on community-dwelling participants 75 yrs of age or older, capable of 
providing consent (MMSE > 12), having bilateral cataracts and being scheduled for first 
eye surgery. Their participants (n= 112) were all recruited from eye clinics, many had 
impaired cognition, and there were even 9 (8%) and 23 (20.5%) who met the clinical 
diagnosis of dementia and MCI, respectively, although only 3 had been seen in a memory 
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clinic prior to the study. All participants (n= 46 with intact and n= 45 with impaired 
cognition) seen at the 1 yr post-surgery follow-up had improvements in VA and visual 
quality of life. Those with MCI and dementia also improved, although to a lesser degree 
than those with cognitive decline but without these diagnoses. Although the outcomes of 
surgery were beneficial, the authors carefully concluded that these results cannot be 
extrapolated to individuals with severe cognitive impairment, as none were included in 
the study. 
 
Many studies have documented a high prevalence of cataract in elderly residents living in 
nursing homes and long term care facilities228,229, however, much less attention has been 
given to the uptake of cataract surgery and its benefits for that population. Although no 
study seems to have documented this issue in an older institutionalized population 
comprised exclusively of individuals with dementia, the SEEING study included a good 
proportion of older individuals with the disease.230 This study reported data on the uptake 
of cataract surgery in nursing homes where assistance with access to the surgery was 
offered to the residents (i.e. intervention), compared to nursing homes where regular care 
was provided to the residents (i.e. usual care). Their results clearly demonstrated that 
there is a better uptake of cataract surgery in nursing homes receiving intervention 
compared to those where usual care is provided (30% vs 2% of residents had surgery). 
The authors, however, found many unexpected barriers to cataract surgery for cognitively 
impaired nursing home residents. The lack of transportation and patients' advocates to 
coordinate the appointments were important barriers in nursing homes where usual care 
was provided. Another important barrier, in 50% of those requiring cataract extraction, 
was the non acceptance of the surgery by the family, the guardians or the residents 
themselves. The rate of refusal was similar when consent was provided by residents 
compared to family/guardians. An additionnal barrier was community ophthalmologists 
refusing to perform the surgery although they had accepted to see residents who would be 
sent to them by the research staff. The authors rightly conclude that if studies can 
demonstrate that cataract surgery improves the quality of life of institutionalized frail 
elderly residents, then programs aimed at removing barriers to surgery will have to be 
implemented. Since, at least one study has been able to make this demonstration. Owsley 
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et al231 showed that nursing home residents undergoing cataract surgery, compared to 
other residents refusing surgery, had improvements in their distance and near VA, 
contrast sensitivity as well as many aspects of their vision-targeted health-related quality 
of life. Their study included residents with mild to moderate dementia, but excluded those 
with more advanced stages of the disease. Thus, as the authors acknowledged, their 
results can unfortunately not be generalized to that nursing home sub-population and 
further studies are required to address this important issue. Importantly, however, their 
study demonstrated the overall benefits of cataract surgery for older institutionalized 
individuals with mild to moderate dementia. Taken together, the studies by Friedman230 
and Owsley231 provide evidence-based data that can be used by clinicians to inform 
residents, family members and guardians on the benefits of cataract surgery for those 
individuals, whenever cataract surgery is required.  
 
There are many issues to consider clinically when facing older residents with advanced 
dementia having visually debilitating cataracts, more so in developed countries where 
health services are readily available. One legitimate question is why was the surgery not 
performed earlier in the person's life, prior to institutionalization or before a cognitive 
deficit evolved into severe dementia. This question brings along the issues of prevention 
and education. Did the person develop the cataract during institutionalization or was it a 
pre-existing undiagnosed cataract that continued evolving ? In either case, a diagnosis of 
cataract should have been made early on after the person had been admitted to the nursing 
home. Therefore, it is suggested that for each newly-admitted resident, the nursing home 
should request a copy of the last eye examination if performed within the previous 1-2 
yrs, or should ensure that a complete eye examination is offered to the resident. This 
would help in the detection and optimization of any uncorrected or not appropriately 
corrected ocular refraction, the detection and treatment of any active ocular pathology, 
and the adjustment of the environment as well as the way care is provided if a visual 
impairment is present. The studies described earlier clearly indicate that cataract surgery 
improves VA and vision-related quality of life in older community-dwelling and 
institutionalized individuals with mild to moderate dementia. One study also 
demonstrated the VA benefits for older institutionalized individuals having more 
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advanced dementia.230 The difficulty the clinician faces in the presence of a resident with 
advanced dementia needing cataract surgery is to help the resident, family, guardian, 
make an informed decision regarding the surgery. This information has to be evidence-
based. There is now some evidence that VA will be improved in these residents,230 but 
there are no data on the overall quality of life provided by this gain in VA. More often 
than not, this is what the family or guardian wants to address. This is really about 
weighing the benefits vs the risks, more so since general anesthesia will usually be 
required for the surgery. As of yet, these data do not exist in the literature because there is 
no vision-related quality of life questionnaire specifically addressing this issue for people 
with more advanced dementia.232 Such a questionnaire has to be built and validated in 
order to evaluate how changes in vision impact the quality of life of institutionalized 
individuals with more advanced dementia. 
 
Eye care professionals keep on stressing the importance of providing regular eye 
examinations every 1-2 yrs for people 65 yrs of age or older.233-236 This is true for 
community-dwelling individuals and it is particularly important for older instutionalized 
people for whom studies have repeatedly reported a higher prevalence of visual 
impairment. Eye care professionals should keep reinforcing this message among older 
patients consulting them, in order to detect and address any oculovisual problem as early 
as possible. If the oculovisual health of older individuals can be optimized when they live 
in the community, then it is hoped that eventually the prevalence of correctable visual 
impairment in those needing institutionalization will not be as high as it is currently. 
Meanwhile, eye care professionals could also assume a more pro-active role in their 
community, reaching out for nursing homes to provide eye care services to residents as 
well as educational programs, knowing that such services are currently not optimal.237 
Educational institutions should also ensure that their curriculum contains the necessary 
theoretical and clinical training in geriatrics so that eye care professionals can confidently 
deliver the special care required by older frail individuals, including those with 
dementia.238,239 In parallel, licensure and certification boards should ensure competency 
of their members in the care of older adults.238,239   
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Correcting refractive error 
As indicated earlier, another important cause of vision loss in nursing homes that might 
be correctable is the inappropriately corrected refractive error. Teresi240 evaluated 3 
groups of older nursing home residents, those receiving optimized ocular refraction, those 
receiving optimized ocular refraction and where the staff received specific training to 
help residents, and a control group receiving standard nursing home care. Their data 
showed less functional decline in residents from the nursing wards where both the 
optimization of ocular refraction and staff training were implemented. On that basis they 
recommended a yearly eye examination for nursing home residents, including the 
optimization of ocular refraction and staff training. Owsley241 examined the effect of 
optimizing ocular refraction for nursing home residents, including those with mild to 
moderate dementia (MMSE≥ 13). In their study, eligible participants had to have an 
uncorrected refractive error of at least one line on a distance acuity chart, in at least one 
eye. They showed that adjusting the ocular refraction improved vision related quality of 
life and decreased symptoms of depression. These results are very important, more so 
considering that in the clinical setting, it was shown that correcting the ocular refraction 
improved the distance VA by 5 lines on average on the regular Snellen chart.44 This latter 
study was retrospective and did not include vision related quality of life assessments, but 
more than half the participants had moderate to severe dementia (MMSE< 15). Here 
again, future studies should evaluate the impact improving VA by optimizing ocular 
refraction has on nursing home residents having moderate to severe dementia. As 
indicated above, a vision related quality of life questionnaire needs to be built and 
validated for that population before such studies can be implemented.232 There are still 
many barriers to eye care for residents in nursing homes and, even when eye care services 
are provided, interventions are not always accepted. Having evidence-based data clearly 
demonstrating the positive outcomes of optimizing ocular refraction on a resident's vision 
related quality of life could potentially improve compliance to treatment.  
 
Reflecting on the benefits of improving vision in dementia 
The benefits of improving vision through the optimal modality (optical, medical, surgical 
or rehabilitation treatment) according to an individual's condition has been amply 
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demonstrated, in multiple domains, for the general older population. Hence, an 
improvement in vision has been associated with a better quality of life,231,241,242 a 
decrease of depressive symptoms231, as well as a decrease in falls243 and injury.244 On the 
other hand, vision loss can contribute to depression,245 isolation,245 disruptive 
behaviors246 and falls.247 Therefore, eye care professionals can confidently offer 
evidence-based therapies to older individuals having an ocular condition necessitating 
treatment, knowing that not only will their vision improve, but so will many other aspects 
of their life. 
 
As indicated earlier, research has now provided some evidence that undergoing cataract 
surgery improves VA and quality of life in older individuals with MCI, as well as those 
with mild to moderate dementia.227, 231 It has also been shown to increase VA in older 
institutionalized individuals with more advanced dementia.230 Furthermore, optimizing 
ocular refraction has been shown to increase VA, improve quality of life and reduce 
symptoms of depression in older institutionalized individuals with mild to moderate 
dementia.233 It has also been shown to increase VA in those with more advanced 
dementia.44  
 
Hence, there is enough evidence for the clinician to confidently indicate to the patient 
with dementia, their family or guardian, that optimizing ocular refraction or undergoing 
cataract surgery should improve VA, as is the case for an older person without dementia. 
There is also enough evidence to inform them that the quality of life of the older 
individual with mild to moderate dementia should improve. However, evidence is still 
lacking for indicating that these interventions will improve the quality of life for those 
affected with more advanced dementia. This certainly should not prevent the clinician 
from offering an intervention for cataract surgery in advanced dementia, but the risks vs 
benefits to go ahead with the surgery should be well weighed and explained and the final 
decision taken together with the patient, the family or guardian, the ophthalmologist, the 
anesthesiologist and the physician caring for this patient. Global peri-surgical care 
adapted for an older frail population should then be provided.  
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Optimizing ocular refraction for improving VA in more advanced dementia is a different 
issue and should not provide too much difficulty, even if evidence for improvement in 
quality of life or other modalities (eg. social isolation, falls) is lacking. It is not as such an 
invasive intervention, and this treatment modality is generally well accepted. The 
clinician can usually base his/her decision to prescribe or modify a prescription based on 
criteria similar to those used for other frail older individuals, which include special 
considerations to the amount of dioptric change and the type of corrective lenses that will 
be prescribed, in view of the risk of falls that is highly prevalent in that population.248 
Falls are effectively a major health problem, knowing that 30% of older individuals 65 
yrs of age and older fall at least once a year249 and that this proportion increases to 48% 
in those 85 yrs and older living at home.250 The incidence rates of falls for older persons 
are greater in nursing homes and hospitals compared to those living in the community.251 
It is also known that 5% of older individuals who fall need to be hospitalized.252 
Additionally, falls leading to trauma represent 10 to 15% of admissions in geriatric 
evaluation units.253 Studies further indicate that falls are more prevalent in older 
individuals having visual impairment.254 Unfortunately, vision remains overlooked in the 
global evaluation of older individuals hospitalized following a fall.255 
 
No studies have investigated specifically the appropriateness of the degree of dioptric 
change or type of ophthalmic lenses required for older individuals with dementia. Until 
these studies are performed, it seems reasonable to apply current evidence-based practice 
developed for frail older individuals to those affected by dementia. One of the most 
important issues is to ensure that the person wearing the lenses will be able not only to 
see well at far and near distance, but will also function optimally and in a secure fashion 
on a daily basis and for all activities requiring mobility if the person is ambulatory. 
Elliott256 has provided a comprehensive overview dealing with that issue for the frail 
older population, with or without visual impairment, including the difficulties these 
individuals face when navigating within their environment. He has conducted several 
studies aimed at understanding the effect of various prescription lenses and their 
magnification effects on falls, gait and postural control in that population. From his own 
studies as well as several randomized control trials, he proposes recommendations on 
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how to prescribe lenses to adjust vision while maintaining safety in frail older individuals 
at risk of falls. First, the case history should be adapted to identify older individuals at 
risk of falls; second, changes in an ophthalmic correction should be conservative to avoid 
magnification effects, distortion or imbalance between the two eyes; third, a change in the 
type of lenses should not be implemented if the individual is well adapted to the one 
currently being worn, and fourth, progressive or bifocal lenses should not be offered to 
those at risk of falls who are used to wearing single vision glasses. In this last instance, it 
is worth considering prescribing two pairs of glasses, for far and near distance, while 
ensuring their appropriate identification and use.  
 
A different set of recommendations have been made by Koch et al.38 to prevent 
uncorrected VA for nursing home residents with dementia. They recommended to: 1) 
label eyewear to provide rapid identification of glasses in case of loss or misplacement, 2) 
provide a second pair of glasses in case they are lost or broken, and 3) ensure that 
residents receive an eye examintion every one or two years. More recently, Kergoat et 
al.257 complemented these with additional recommendations for older institutionalized 
individuals, such as: 1) ensuring that the proper lens prescription be worn for the proper 
viewing distance, 2) a sitting position and adequate level of illumination for activities 
such as reading and television, 3) the regular cleaning of ophthalmic lenses for residents, 
4) taking a picture of the glasses as well as the individual while wearing the glasses to 
place in the clinical file, and 5) an analysis of each resident's prescription glasses and the 
writing of the prescription and type of lenses (single vision, type of bifocal/multifocal 
lenses) in the file. For those having visual impairment, they also suggested that 
adaptations be made, such as keeping objects in the same place within the room, 
removing obstacles that can impair safe navigation, optimizing illumination and contrast 
in the room, corridor and for the various activities, minimizing glare, introducing oneself 
to the resident and explaining the reason of the visit and activities/care to take place. 
These recommendations and adaptations are particularly important for a person affected 
by dual visual and cognitive deficiency, since having both deficits can put the individual 
at increased risk of negative consequences.258 Not seeing well (vision deficiency) and not 
being able to judge appropriately the environment (cognitive deficiency) can place these 
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individuals at more risk, such as being lost in time and space, being socially isolated, or 
experiencing a sense of insecurity. It is important to remember that the primary objective 
of care for individuals with dementia is to preserve and promote their quality of life.259 It 
is known that optimizing vision contributes to increasing quality of life, and although a 
person with advanced dementia might not be able to pursue certain activities such as 
reading, they certainly can benefit from others such as socializing, interacting with 
relatives, recognizing faces, looking at family pictures, all of which are facilitated by 
adequate vision. 
 
Eye care for older individuals with cognitive impairment 
 
As mentioned earlier, there is an aging of the population260,261 that will accelerate in the 
coming years,260 the prevalence of dementia is higher in the "oldest old", i.e. those 85 yrs 
of age or older16 and additionally, more than 50% of people having dementia remain 
undiagnosed worldwide.262 It is therefore reasonable to anticipate that many of the older 
individuals consulting for eye care will have undiagnosed cognitive deficits or even 
dementia. Eye care professionals should be aware of these statistics, as well as the pivotal 
role they can play in helping these individuals, since a large proportion of people who 
consult them on a regular basis are those 65 yrs of age or older1,263 Furthermore, visually 
related symptoms such as difficulty in reading, not recognizing familiar objects, spatio-
temporal disorientation, may develop early on in people with dementia264,265  which may 
entice them to consult an eye doctor rather than a medical doctor.  
 
As reviewed in this paper, there is a rapidly growing number of studies reporting 
oculovisual changes in individuals with dementia. Although some of these reports 
suggest that the data could potentially serve as biomarkers for dementia, the strength of 
the evidence is not sufficient as of now for any single test to serve as early diagnosis of 
the disease during the clinical eye examination. In fact, very promising biomarkers for the 
early diagnosis of various types of dementias have been studied intensively worldwide in 
several research areas for years but have not yet permeated the primary-care medical 
clinical environment for many scientific, financial and ethical reasons.266-270 
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In spite of that, eye care clinicians can certainly keep in mind the numerous results that 
have emerged in the field of vision research in the day-to-day evaluation of older 
individuals presenting in their office. Case history, VA, colour vision, stereoacuity, visual 
fields, pupillary function, ocular motilities, evaluation of the anterior and posterior 
segments of the eye, and even imaging of the ocular structures are performed routinely 
during an eye examination. The eye doctor can certainly add key questions in the case 
history to see if a person has difficulty reading such as losing their place, problems with 
orientation in time and space, difficulty naming or recognizing familiar objects, bumping 
into objects, VH, etc. At the outcome of the examination, the clinician will be able to 
judge if any reported symptoms are difficult to match with the results of the eye 
examination. During the VA testing, can the person easily read the letters in a fluent 
fashion, are the instructions easy to follow, is the person always starting over and over 
from the top of the chart when prompted to read the smaller letters, is it taking much 
longer to read the letters compared to others in the same age-group. Can the person name 
easily the numbers on the colour plates, if not, can they easily match the coloured 
capsules on a D15 test. When performing the ocular motilities, are the pursuits smooth or 
saccadic, when doing saccades are the eyes right on target or always erratic, is fixation 
easy and sustained. In the evaluation of the fundus, is there a thinning of the RNFL, is the 
optic nerve head suspicious. In the end, it may not be a single test that can make the 
clinician suspicious, but rather the way in which the older person perfoms at the various 
tests, any change in behavior of a person already known to the eye doctor compared to 
previous visits at the office, as well as the overall performance where test results do not 
match between themselves and/or with the reported symptoms. When in doubt, the 
clinician may ask additional open questions allowing the person to voice any concerns 
with their health, the person can be scheduled for a follow-up evaluation or can also be 
advised to see his/her family doctor for further investigations. Some studies have even 
evaluated the possibility of screening for cognitive function in the ophthalmology 
clinic.237,245 Additional research is needed to evaluate the ability of such screening to 
correctly detect older individuals who will in fact be identified as having a cognitive 
deficit or dementia at the outcome of the medical investigation. If studies demonstrate 
that this type of screening is effective, then clinicians will have to secure appropriate 
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mechanisms to ensure access to medical evaluation for individuals testing positive, before 
using such tests in their office. Ophthalmologists and optometrists see a large proportion 
of individuals 65 yrs of age or older in consultation1,263 and they could play a role in 
helping detect cognitive deficits in the older population. The eye care clinical setting 
seems particularly adequate for that purpose considering the visual-type symptoms 
expressed by individuals with cognitive deficits, as well as the large amount of research 
results linking various aspects of the visual system to dementia. Clinicians trained in the 
administration and interpretation of these tests could easily screen older individuals for 
cognitive function with simple validated questions, a short version of the MMSE or the 
Mini-Cog for example.  
 
The eye examination offered to older individuals residing in nursing homes is a different 
issue. Here, the cognitive deficit or the diagnosis of dementia is usually known, and 
dementia is often the reason why a person is being institutionalized.272 There is also very 
good agreement in the scientific literature that the prevalence of uncorrected refractive 
errors and ocular pathology is high and higher than in the community and that eye care 
services to these residents are not optimal.237,273 The role of the eye care professional is to 
provide access to the eye examination, adapt the eye examination to maximize the 
information obtained while minimizing fatigue, counsel the resident, family, guardian, 
regarding any diagnosis or treatment, help other health care professionals when 
differential diagnoses are needed, as well as counsel the nursing home personnel on how 
to adjust their care and the environment to help the resident whenever a visual 
impairment is present. Performing an eye examination for residents with mild to 
moderate dementia does not usually present any major difficulty. It might simply require 
more time and the instructions need to be provided clearly, in short sentences that are not 
overcrowded with too many levels of decision-making processes. Additionally, since 
divided attention is already problematic with aging, the eye examination should be 
conducted in a calm environment and each step of a different test explained separately. 
Residents with more advanced dementia, on the other hand, may render the eye 
examination more challenging in terms of communication and collaboration. Minimally, 
however, an evaluation of the VA, the ocular refraction and the ocular health should be 
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provided and vision should be optimized, as much as possible.44 The examination room 
has to be physically adapted to accommodate any type of wheelchair and/or bedchair, the 
ophthalmic chair should ideally be on a sliding platform to be replaced by the wheelchair 
if required, and each diagnostic instrument chosen to ease access to the patient's eyes, 
portability being very important. Although for some residents it might not be possible to 
do any test, it is usually possible to do an eye examination or at least part of it on the 
majority of residents.44  
 
 
Discussion and conclusion 
As reviewed here, dementia has been associated with a variety of visual problems 
including defects in primary vision such as VA, colour vision, visual fields, eye 
movements, and more complex aspects of vision such as in reading ability and 
visuospatial function. VA is not always easy to measure in dementia, especially in the 
advanced stages, and some studies have indicated that it was impaired in the later stages 
of the disease. Alternatively, it might also be that we do not have the right tool to measure 
VA in a person with severe dementia not able to offer sufficient collaboration to perform 
the test. Defects in pupillary function and in saccadic and smooth pursuit eye movements, 
are also common in different dementias. In AD, deficits in colour vision, CSF, 
stereoacuity, backwards masking, reading, and object recognition have been documented, 
although some results remain controversial. Defects in motion detection, visual fields, 
CFFF, ERG and VEP have also been reported in AD, but require further study. Visual 
dysfunction in VD may be very similar to that in AD with the possible exceptions that 
stereoacuity deficit might be greater and performance on event-related potential tasks 
poorer than in AD. In FTD, problems involving saccadic eye movement, mutual gaze, 
and in facial recognition may be especially common. DLB and PDD are both 
characterized by prominent VH, eye movement problems, and difficulty with visuospatial 
orientation. When VH are present however, it is important to eliminate ‘Charles Bonnet 
syndrome’, and if no diagnosis of this disorder is made, to refer the patient for further 
investigation.274,275 Pathological changes have also been reported to affect the retina, 
optic nerve, and visual areas of the brain in dementia. Many of these oculovisual changes 
occur across dementias, are controversial, and often based on limited numbers of subjects 
 36 
and no single oculovisual feature can be regarded as diagnostic of any specific dementia. 
Nevertheless, VH may be more characteristic of DLB and PDD than AD or FTD and 
variation in saccadic eye movements may help to distinguish between parkinsonian 
syndromes and AD from FTD. 
 
Although the oculovisual symptoms summarized above might be quite variable across 
individuals, although the literature still has many gaps and is often controversial with 
different studies reporting conflicting conclusions, although individual tests are not 
specific to particular dementias and cannot really identify individual disorders, and 
although laboratory-based tests used to investigate vision in dementia do not always 
translate easily to clinical testing in practice, there is ample evidence in the literature to 
conclude that vision is affected in dementia. Additional research will need to address the 
discrepancies reported in the literature in order to provide a clearer picture of the changes 
affecting the oculovisual system in the various dementias. Research into potential 
oculovisual biomarkers of various types of dementia should also be pursued, in trying to 
help with early diagnosis. Finally, research is also needed to continue addressing clinical 
issues that will help improve the care provided to older individuals affected by dementia.  
 
In conclusion, dementia is a neurodegenerative disease whose prevalence will continue to 
increase in the next decades along with the aging of the population. The disease is 
associated with a variety of oculovisual problems for which affected individuals will 
likely seek eye care services. Eye care professionals will need to keep well informed of 
the growing literature in the area, be attentive to signs and symptoms that might alert 
them to potential cognitive impairment, and be able to adapt their practice and clinical 
interventions to best serve patients with dementia.  
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Table 1. A classification of the dementias 
________________________________________________________________________ 
Group Definition     Examples 
 
A Neurodegenerative disorders, aetiology Alzheimer’s disease  
uncertain Dementia with Lewy bodies  
       Parkinson’s disease dementia 
Fronto-temporal dementia  
    Progressive supranuclear palsy 
    Corticobasal degeneration  
B Dementia associated with systemic  Infection (syphilis, tuberculosis, 
 disease      inclusion body encephalitis,  
       Infective endocarditis); 
       Vascular dementia (cerebral  
       arteriosclerosis, arteritis); 
       Intoxication (sedatives, alcohol, 
       narcotics); 
       Metabolic disorders (uremia,  
       chronic hepatic insufficiency, 
       hypoglycemia, hypothyroidism,  
       pernicious anaemia, pellagra); 
       Neoplasms  
C Dementia associated with viruses  Progressive multifocal 
 or prions     leucoencephalopathy,  
Subacute sclerosing panencephalitis,  
Creutzfeldt-Jacob disease  
D Dementia with miscellaneous causes  Brain abscess, Trauma,  
 Hydrocephalus, Chronic meningitis 
_________________________________________________________________________________________________ 
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Table 2. Overview of visual dysfunction in various dementias 
________________________________________________________________________ 
Visual feature   Dysfunction 
________________________________________________________________________ 
Visual acuity Normal in early stages of AD, may deteriorate in avanced 
disease.40,43,45,62 Limited data on other dementias. 
 
Colour vision Controversial but likely to be affected in AD, DLB and 
PDD.47-53 
 
Stereoacuity Impaired in AD and VD.41,54-56 
 
Contrast sensitivity Impaired in AD and VD.59-62  
 
Motion detection Higher thresholds necessary for detecting a moving 
stimulus in AD.69,70 
 
CFFF Controversial, can be impaired72 or normal in AD.41 
 
Visual masking Significantly affected by a backward patterned mask 
stimulus in AD.58,78,79 
 
Visual fields Limited data but evidence for defects in AD.82 rCBF 
measurements indicate potential for visual field deficits in 
DLB.85-87 
 
Pupillary function Controversial. Significant response to mydriatics in AD.89-
96 
 
Eye movements Most significant in PDD and DLB. Defects in fixation, 
decline in saccadic latency, undershooting of target in AD. 
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Saccadic latency prolonged in FTD. Abnormal saccadic 
and smooth pursuit eye movements and convergence in 
DLB.48,98-103,106,117 
 
EEG Increase in slow activity and a smaller decrease in fast 
activity in AD; no increase in slow activity but an increase 
in fast activity in FTD118. Reduction in synchrony of the 
slow frequency bands in VD.119 Changes also in DLB.120 
 
ERG Controversial in AD.123-128,212 Defects likely in DLB.129 
 
VEP Controversial in AD but flash response could be delayed 
and pattern response normal.131-136 
 
Visual event EP Greater response in DLB than AD but greater in AD than 
FTD.138,139 
 
Complex functions  Defects in reading140, visuospatial function48,141,142, and 
object identification in AD.47 AD and VD have similar 
deficits.147 Visuospatial function affected in DLB but less 
so in AD.155 Relative preservation of visuospatial function 
in FTD.156 
 
Visual hallucinations Common in DLB and PDD and less frequent in AD and 
FTD.129,130,159-176  
________________________________________________________________________ 
Abbreviations: Disorders: AD = Alzheimer’s disease, FTD = Frontotemporal dementia, 
VD = Vascular dementia, PDD = Parkinson’s disease dementia, DLB = Dementia with 
Lewy bodies; Visual features: CFFF = Critical flicker fusion frequency, EEG = 
electroencephalogram, ERG = Electroretinogram, VEP = Visual evoked potential, Visual 
event EP = Visual event-related potentials 
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Legend to Figure 
 
Fig 1. Factors involved in visual hallucinations in dementia with Lewy bodies (DLB). 
Abbreviations: LB = Lewy bodies, CAT = Choline acetyltransferase 
 
 
